Copper homeostasis and cuproptosis in health and disease

Copper lives a double life in biology. On one side, it’s indispensable—fueling enzymes that move electrons, detoxify radicals, and stitch collagen. On the other side, tip the balance by a little, and copper turns destructive. Min and Wang lay out that tightrope beautifully: a multilayered homeostatic system moves copper from your gut to your mitochondria and to the bile duct, with checkpoints everywhere. And into that landscape drops a new idea with sharp edges—cuproptosis—the notion that excess intracellular copper can hijack a very specific mitochondrial vulnerability and kill a cell from the inside out. Start at the beginning: you eat copper, mostly absorbed in the duodenum and small intestine. Specialized reductases—the STEAP proteins and duodenal cytochrome b—convert copper to the form that the importer CTR1, also called SLC31A1, prefers. Once inside enterocytes, copper hitches rides on albumin, histidines, and big carrier proteins in the blood, heading straight for the liver. Hepatocytes bring it in through the CTR1 transporter again, then hand it off to chaperones. The COX17 chaperone takes copper toward cytochrome c oxidase by way of assembly factors like SCO1 and SCO2. The CCS chaperone loads copper into the antioxidant enzyme SOD1. The ATOX1 chaperone shuttles it to the export pumps, ATP7A and ATP7B, which tuck copper into the secretory pathway or send it out of the cell. The liver is the pivot: it can return copper to the bloodstream for delivery to tissues, or send the excess into bile. Biliary excretion is the main way the body gets rid of copper. All of this is tuned like a thermostat. If copper is high, cells throttle back CTR1; if it’s low, they dial it up. ATP7A in the intestine sits on the basolateral side of enterocytes, moving copper into portal blood; ATP7B in the liver channels it into bile to keep the organ from hoarding too much. ATP7A also helps move copper across barriers like the placenta and the blood-brain barrier. Systemically, high copper intake can push the gut to absorb less and the liver to excrete more; scarcity flips those dials in the opposite direction. When these levers fail, you see it in the clinic. Menkes disease—mutations in ATP7A—strands copper at the entry gate, starving enzymes and derailing development. Wilson’s disease—defects in ATP7B—clogs the exit, stockpiling copper in the liver and brain. Into that backdrop comes the new mechanism. Cuproptosis, as first pinned down by Tsvetkov and colleagues and reviewed by Chen, Min, and Wang, isn’t apoptosis, it isn’t ferroptosis, and it isn’t a generic oxidative burn. It’s copper exploiting a particular chemistry in the mitochondria. The trigger is copper binding directly to lipoylated proteins in the tricarboxylic acid cycle—the enzymes that carry little lipoic acid arms used for acyl transfers. One of those, the DLAT protein, a subunit of the pyruvate dehydrogenase complex, becomes a hub. Copper latches onto the lipoylated DLAT, encourages aggregation driven by disulfide bonds, and the mitochondrion begins to choke on its own stuck machinery. In parallel, iron-sulfur cluster proteins begin to falter, stripping electron transport and enzyme function. That combination—protein aggregation plus iron-sulfur collapse—creates proteotoxic stress that ends in cell death. The key is that susceptibility depends on lipoylation itself. The cell’s lipoylation pathway—regulated upstream by ferredoxin one and lipoic acid synthetase—sets the stage. In genome-scale CRISPR screens, knocking out ferredoxin one or lipoic acid synthetase made cells resistant to copper-induced death. When those genes are gone, lipoylation drops, DLAT doesn’t aggregate, and cells survive. You can see the metabolic footprint too: pyruvate and alpha-ketoglutarate build up when lipoylation stalls, consistent with a jam in the pyruvate dehydrogenase and tricarboxylic acid flow. That is a clean genetic handle on the mechanism, and it anchors the idea that cuproptosis is not just “too much copper,” but “too much copper meeting the wrong mitochondrial chemistry.” Drugs that move copper across membranes make that point louder. Elesclomol, a copper ionophore, is a favorite tool in this literature. When cells take up elesclomol-bound copper, cuproptosis can kick in at very low intracellular copper—on the order of tens of nanomolar; in Tsvetkov’s work, as little as 40 nanomolar was enough. Block apoptosis, necroptosis, ferroptosis, even throw in antioxidants like N-acetyl cysteine—the cells still die. Grab the copper with a chelator and the death stops. That rescue is the tell. Copper isn’t just correlated with the kill switch; it is the kill switch. Mitochondria sit squarely in the crosshairs. When copper floods in, tricarboxylic acid linked metabolites drift off course, and the electron transport chain loses its bite. If you inhibit respiratory complexes I and II ahead of time, you can blunt copper-induced death, which lines up with the idea that cuproptosis needs an active, lipoylation-rich tricarboxylic acid engine to take hold. Redox buffering in the organelle matters too. Studies point to mitochondrial glutathione as a brake, dampening lipoylation-dependent aggregation and slowing the cascade. And in vivo, the story rhymes: mice lacking the Atp7b gene, a model of Wilson’s disease, show reduced levels of lipoylated enzymes and iron-sulfur proteins in the liver, a biochemical snapshot that looks strikingly like the cuproptosis signature. It’s also useful to contrast what cuproptosis looks like with its cousins. Ferroptosis famously shrinks mitochondria and densifies their membranes. Those hallmarks haven’t shown up here. The shapes and textures are different, underscoring that we’re looking at a separate program with a mitochondrial, but not ferroptotic, phenotype. Chen, Min, and Wang are careful about that distinction—same organelle, different choreography. Once you see copper through this lens, a lot of clinical territory starts to look connected, even if the wires aren’t all mapped yet. In Menkes disease, copper can’t reach its targets: lysyl oxidase falters, cytochrome c oxidase assembly suffers, and tissues that rely on those enzymes—heart, brain, connective tissue—pay the price. Kaler and others have detailed congenital heart defects and neurodevelopmental issues in that setting. In Wilson’s disease, the opposite problem—copper overload—comes with mitochondrial dysfunction in the liver and brain and sometimes the heart. The ATP7A and ATP7B logistics chain that normally meters copper across the placenta, into the central nervous system, and out into bile is doing double duty: keeping cuproenzymes happy and keeping cuproptosis at bay. Step back to neurodegeneration and cancer, and the threads extend. Work in Alzheimer’s disease ties copper to amyloid beta aggregation and tau phosphorylation; in amyotrophic lateral sclerosis, copper’s relationship with SOD1 and mitochondrial stress has long been a theme. Tumors, meanwhile, often live on a knife-edge of metabolism, with elevated copper and a taste for mitochondrion-targeting drugs. Across these fields, Min and Wang counsel caution: the associations are solid, but causality is still being nailed down. Therapeutically, two tracks emerge. The first is the obvious one: when copper is hurting you, take it away. Chelators like tetrathiomolybdate, trientine, and D-penicillamine have been standard in Wilson’s disease for years. Recent clinical work adds nuance. In comparative settings, tetrathiomolybdate has been linked to slower disease progression than trientine, and a phase two program with WTX101—the bis-choline salt of tetrathiomolybdate—reported rapid stabilization of copper balance with concurrent improvements in liver function. That maps cleanly onto the mechanism we’ve been talking about: reduce the copper pool, cut off the trigger for aggregation, and you should lower the risk of cuproptosis-like injury in copper overloaded tissues. The second track flips the script for oncology. If a tumor is wired for heavy mitochondrial metabolism and its tricarboxylic acid enzymes are richly lipoylated, copper ionophores can become precision weapons. Preclinical work with designer delivery systems bears that out. A copper-carrying construct dubbed GOx@[Cu(tz)] knocked down bladder tumor growth by about ninety-two percent in mice. Elesclomol’s clinical history tells a similar story with a metabolic twist: in a phase three melanoma study, patients with low plasma lactate dehydrogenase—think more oxidative metabolism—tended to do better. That’s exactly what the mechanism would predict. There’s a parallel line with disulfiram-copper complexes too. They cross the blood-brain barrier, target aldehyde dehydrogenase-positive cancer stem cells, and in glioblastoma combinations with temozolomide have shown tolerable safety with signals of longer time before progression. Put simply, push copper into the right mitochondria, and cuproptosis can be a feature, not a bug. Here’s the catch: we don’t yet have great ways to pick the “right mitochondria.” Biomarkers specific to cuproptosis are still aspirational. Chen and colleagues suggest watching the lipoylation state of tricarboxylic acid enzymes or the aggregation status of DLAT as proxies. You can imagine composite readouts—high lipoylation, robust oxidative phosphorylation, certain transporter signatures—flagging likely responders to copper ionophores. But that work is early. And even if you can find the patients, you’ll still need to deliver copper or chelators where they need to go without lighting fires elsewhere. Targeted delivery and safety aren’t afterthoughts here; they’re the ballgame. There are also mechanistic gaps that matter for translation. We know copper binds lipoylated enzymes and we see disulfide-based aggregation, iron-sulfur proteins falling apart, and proteotoxic stress. What we don’t fully grasp is the propagation: how does that initial aggregation ripple through the mitochondrial quality control systems, the electron transport chain, and back to nuclear stress responses? Do other pathways pitch in under different metabolic states? And in human disease, when you biopsy a liver with Wilson’s disease or profile a neurodegenerating cortex, how often do you find the biochemical fingerprints of cuproptosis, not just nonspecific oxidative injury? So where does that leave us? With a sharp new lens and a lot of careful work ahead. The strongest pieces on the table are the genetic levers—ferredoxin one and lipoic acid synthetase lighting up in CRISPR screens—the pharmacology that toggles death on with ionophores and off with chelators, and the in vivo echoes in Wilson’s models. They stitch together into a coherent story: copper can become lethal by clamping onto lipoylated mitochondrial enzymes, and the cell’s own lipoylation machinery sets the sensitivity dial. If you manage copper deftly—reduce it where it accumulates and deliver it where tumors are most primed—you can move the biology in your favor. And that loops us back to the opening paradox. Copper is essential and dangerous because it moves electrons with gusto. Biology built a choreography—CTR1 at the gut lining, chaperones in the cytosol, ATP7A and ATP7B at the gates—to capture that energy without getting burned. Cuproptosis tells us how thin that margin is. It also gives us handles to pull. As Min, Chen, and Wang argue, the next advances will likely come from pairing that mechanistic clarity with smarter patient selection and smarter delivery. Keep the copper where it belongs. And, when the time is right, send it exactly where it can do the most good.